Recommendation of the President – Itulazax (Betula Verrucosa)

On 30 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 160/2025 on the reimbursement of the medicinal product Itulazax (Betula Verrucosa), sublingual lyophilisate, 12 SQ-Bet for the treatment of allergic rhinitis and/or conjunctivitis caused by a family of allergens homologous to birch allergen in children and adolescents aged 5-17 years, diagnosed on the basis of clinical history and a positive allergy test for the birch homolog family (skin prick tests and/or specific immunoglobulin E)

Publication in Public Information Bulletin (BIP) >>